MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 05-11-2026
Cellectis S.A. Operating Income 2011-2026 | CLLS
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Cellectis S.A.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -33.1 M | -59.6 M | -97.3 M | -89.7 M | -131 M | -85.4 M | -124 M | -105 M | -92.6 M | -67.3 M | -31 M | -6.97 M | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -6.97 M | -131 M | -76.9 M |
Quarterly Operating Income Cellectis S.A.
| 2025-Q4 | 2025-Q2 | 2024-Q4 | 2024-Q2 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -33.1 M | -9.59 M | -59.6 M | -17.2 M | -97.3 M | -67.7 M | -23.7 M | - | - | - | - | - | - | -37.5 M | - | - | - | -33 M | - | - | - | -35.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -9.59 M | -97.3 M | -41.4 M |
Operating Income of other stocks in the Biotechnology industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
FSD Pharma
HUGE
|
-15.3 M | - | 5743.5 % | $ 69.7 M |  Canada |
 |
MorphoSys AG
MOR
|
-508 M | - | 2.43 % | $ 254 M |  Germany |
 |
Happiness Biotech Group Limited
HAPP
|
-6.78 M | - | 1.35 % | $ 17.8 M |  China |
 |
AgeX Therapeutics
AGE
|
-24 M | - | -10.17 % | $ 12.2 K |  USA |
 |
Deciphera Pharmaceuticals
DCPH
|
-211 M | - | - | $ 2.18 B | USA |
 |
Genfit SA
GNFT
|
31.8 M | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
-14.3 M | - | -13.47 % | $ 169 M | France |
 |
AstraZeneca PLC
AZN
|
13.7 B | - | - | $ 96.9 B |  Britain |
 |
BioNTech SE
BNTX
|
-1.4 B | $ 89.59 | - | $ 21.7 B | Germany |
 |
Compugen Ltd.
CGEN
|
31.3 M | $ 2.22 | - | $ 207 M |  Israel |
 |
Coherus BioSciences
CHRS
|
-181 M | $ 1.58 | - | $ 185 M | USA |
 |
Athira Pharma
ATHA
|
-102 M | - | - | $ 269 M | USA |
 |
Abcam plc
ABCM
|
-10.1 M | - | - | $ 4.9 B | Britain |
 |
Galera Therapeutics
GRTX
|
-2.54 M | - | -32.59 % | $ 7.61 M | USA |
 |
Midatech Pharma plc
MTP
|
-8.64 M | - | -18.52 % | $ 27.3 M | Britain |
 |
Affimed N.V.
AFMD
|
-107 M | - | -34.95 % | $ 21.5 M | Germany |
 |
Checkmate Pharmaceuticals
CMPI
|
-61.5 M | - | - | $ 231 M | USA |
 |
Celyad Oncology SA
CYAD
|
-40.9 M | - | - | $ 12.5 M |  Belgium |
 |
Berkeley Lights
BLI
|
-98.1 M | - | -7.31 % | $ 87 M | USA |
 |
Celldex Therapeutics
CLDX
|
-287 M | $ 29.93 | - | $ 1.99 B | USA |
 |
Generation Bio Co.
GBIO
|
-142 M | - | - | $ 344 M | USA |
 |
Akero Therapeutics
AKRO
|
-285 M | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
-86.8 M | - | 0.23 % | $ 488 M | USA |
|
Enlivex Therapeutics Ltd.
ENLV
|
-15 M | $ 0.79 | - | $ 36.1 M | Israel |
 |
Ayala Pharmaceuticals
AYLA
|
-37.5 M | - | - | $ 7.46 M | Israel |
 |
Esperion Therapeutics
ESPR
|
60.3 M | $ 3.13 | - | $ 651 M | USA |
 |
Eton Pharmaceuticals
ETON
|
-844 K | $ 28.9 | - | $ 778 M | USA |
 |
Cyclacel Pharmaceuticals
CYCCP
|
-8.43 M | - | -4.36 % | $ 27 M | USA |
 |
Freeline Therapeutics Holdings plc
FRLN
|
-98.4 M | - | - | $ 384 M | Britain |
|
Forte Biosciences
FBRX
|
-70.7 M | $ 16.69 | - | $ 216 M | USA |
 |
Gracell Biotechnologies
GRCL
|
-625 M | - | - | $ 3.37 B | China |
 |
Anika Therapeutics
ANIK
|
-11.1 M | $ 14.79 | - | $ 212 M | USA |
 |
Advaxis
ADXS
|
-36.3 M | - | -9.65 % | $ 45.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
-10.7 M | - | 5.93 % | $ 314 M | Canada |
 |
Aeglea BioTherapeutics
AGLE
|
-210 M | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
-412 M | - | - | $ 867 M | Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
-17.7 M | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
-55.7 M | - | 1.93 % | $ 17.4 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-9.95 M | $ 3.16 | - | $ 5.2 M | Israel |
 |
CRISPR Therapeutics AG
CRSP
|
-665 M | $ 56.95 | - | $ 5.12 B |  Schweiz |
 |
Aptinyx
APTX
|
-62.6 M | - | -39.0 % | $ 4.57 M | USA |
 |
Albireo Pharma
ALBO
|
-123 M | - | -0.23 % | $ 916 M | USA |
 |
Galectin Therapeutics
GALT
|
-20.1 M | $ 2.38 | - | $ 152 M | USA |